Special Issue "Lymphoma Biology, Pathology and Stem Cells"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 9 August 2024 | Viewed by 95

Special Issue Editor

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Interests: molecular pathogenesis of lymphoma and leukemia; tumor immunology and GVHD; sickle cell disease; thrombosis; vascular biology; viral infections and cancerogenesis; cancer stem cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Malignant lymphomas are a heterogeneous group of neoplasms which are clinically variable from indolent to aggressive and usually diagnostically challenging. With the advance of cellular molecular biology, genomics, cancer immunology and stem cell research, understanding of the pathogenesis of lymphomas is increasing.  The improved knowledge leads us to better molecular characterization, more objective and accurate diagnostic criteria, more effective risk stratification and better treatments for potentially curing the disease. This Special Issue invites the submission of papers sharing new knowledge and discussing the latest advances in the diagnosis, treatment and prognosis of lymphomas, and opens perspectives to future clinical trials.  

The main interest includes comprehensive studies of the clinicopathological and molecular features of nodal and extra-nodal lymphomas. It will provide a unique forum to address frequently encountered diagnostic problems, and highlight novel and emerging biomarkers and evolution of new treatment via target therapy, hematopoietic stem cell transplant, immunotherapy and CAR-T therapy. An exciting aspect for the issue will be the application of genomic profiling in molecular classification of aggressive lymphomas, and targeted therapy for the driver mutations in order eradicate the cancer stem cells.  We welcome research papers or review articles from novel perspectives to focus on the following topics reflecting the new area in the diagnosis and treatment of lymphomas:

  • Lymphoma pathology: new entities, phenotypic studies of T/NK or B-cell lymphomas, WHO vs. ICC, changing the paradigms in the molecular classification of lymphomas;
  • Lymphoma biology: molecular studies on the regulation of cell cycle activation, driver mutations in initiation metabolic control of lymphomagenesis, progression and transformation of lymphomas;
  • Basic and translational studies of lymphoid cells and the immune cell microenvironment;
  • Lymphoma stem cells, cancer metabolism, cooperative genetic and epigenetic interactions in normal and transformed lymphoma cells;
  • Tumor immunology: searching for tumor antigens as targets for vaccine strategies, HSCT, new strategy improving the CAR-T and immunotherapy in patient selection and monitoring the prognosis.

Prof. Dr. Mingyi Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • lymphoma biology
  • pathology
  • CAR-T
  • immunotherapy
  • stem cell transplant

Published Papers

This special issue is now open for submission.
Back to TopTop